Últimas noticias sobre Novartis (NYSE:NVS) Bolsa

Novartis

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

News

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ASPN

Los analistas de Wall Street degradaron varias acciones clave. Descubre cuáles y cómo podría impactar en el mercado.

Grandes cambios en calificaciones de acciones: ¿Cómo afectará a tu cartera de inversión?

Novartis AG

NEVADA SUNRISE METALS CRP by NEVADA SUNRISE METALS CORP.

Nevada Sunrise Metals Corp

NOVUS HLDGS LTD SHS by NOVUS HLDGS LTD SHS

Novus Holdings Ltd

Envista Holdings Corporation Common Stock

Envista Holdings Corp

Legal

Ird Nvs pus Genetics Inc Filed Complaint For Patent Infringement Of Certain Ryzumvi Patents Against Sandoz In District Of New Jersey; Complaint Seeks, Among Other Relief, Equitable Relief Enjoining Sandoz From Infringing Ryzumvi Patents

On Wednesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) announced safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in a broad population of patients aged two to &lt;18 years with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">spinal muscular atrophy (SMA)</a>.
In the Phase 3 STEER study, <a target="_blank" href="https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-demonstrate-meaningful-efficacy-and-safety-results-intrathecal-onasemnogene-abeparvovec-broad-patient-population-sma" rel="noreferrer noopener">treatment</a> with OAV101 IT led to a statistically significant 2.39-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE), an assessment of motor ability and disease progression, vs. 0.51 points in the sham control arm.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43629559/novartis-to-beef-up-heart-disease-offering-with-3-billion-blackstone-backed-anthos-therapeutics-deal" rel="noreferrer noopener">Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal</a>
Novartis <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-study-meets-primary-endpoint-children-and-young-adults-sma" rel="noreferrer noopener">released</a> topline data from the Phase 3 STEER study in December 2024.
In the Phase 3b STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Spinraza (nusinersen) or Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Evrysdi (risdiplam) demonstrated stabilization of motor function over 52 weeks of follow-up.
The results add to the growing body of evidence within the OAV101 IT development program, which has evaluated a broad population of over 170 patients with SMA, spanning a total of over 6.4 years across the STEER, STRENGTH, and Phase 1/2 STRONG studies.
OAV101 IT is an investigational gene replacement therapy designed to directly address the genetic root cause of the disease by replacing the nonworking&nbsp;SMN1 gene with a single dose.
In the registrational STEER study, efficacy and safety were studied in treatment naïve patients with SMA Type 2, aged two to less than 18 years, who could sit but had never walked independently. Key findings:
<ul>
<li>The trial met its primary endpoint of change from baseline to 52 weeks in HFMSE score, with OAV101 IT demonstrating a statistically significant 2.39-point improvement on the HFMSE vs 0.51 points in the sham group.</li>
<li>All secondary endpoints consistently favor OAV101 IT, despite not achieving statistical significance due to the pre-planned multiple testing procedure.</li>
</ul>
The open-label Phase 3b STRENGTH study evaluated the safety, tolerability and efficacy of OAV101 IT in patients with SMA aged two to less than 18 years who had discontinued treatment with nusinersen or risdiplam.&nbsp;Key findings:
<ul>
<li>OAV101 IT demonstrated a favorable safety profile that was consistent with the STEER study.</li>
<li>The motor endpoint of efficacy, HFMSE, demonstrated stabilization for the overall study population over 52 weeks. The increase from baseline to 52 weeks in HFMSE least squares (LS) total score was 1.05.</li>
</ul>
Price Action: NVS stock is down 0.75% at $111.38 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44397369/japan-airlines-orders-more-boeing-737-8-jets-amid-global-fleet-expansion-plans" target="_blank" rel="noreferrer noopener">Japan Airlines Orders More Boeing 737-8 Jets Amid Global Fleet Expansion Plans</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Large Cap

Health Care

General

BIIB

RHHBY

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy

<a href="https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-sees-radioactive-cancer-drugs-becoming-10bn-business-CEO" title="https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-sees-radioactive-cancer-drugs-becoming-10bn-business-CEO">https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-sees-radioactive-cancer-drugs-becoming-10bn-business-CEO</a>

'Novartis Sees Radioactive Cancer Drugs Becoming $10B Business: CEO' - Nikkei Asia

Telemedicine operator Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has entered a pharmacy integration agreement with Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Weight Care Program</a>.
Last year, Eli Lilly&nbsp;announced a&nbsp;new&nbsp;website allowing patients to get a prescription for weight loss through a telehealth provider,&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" rel="noreferrer noopener">marking an industry first</a>.
The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44164208/teladoc-health-adds-glp-1-self-pay-option-to-comprehensive-weight-care" rel="noreferrer noopener">used for obesity treatment</a>.
Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42970274/teladoc-shares-surge-as-amazon-partnership-fuels-push-for-consumer-centric-healthcare" rel="noreferrer noopener">Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare</a>
Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.
Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;recently introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
In February, Teladoc reported fourth-quarter revenue&nbsp;of $640.5 million, down 3% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989576/teladoc-health-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">consensus estimates</a>.
Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44167381/target-hospitality-secures-five-year-lease-with-corecivic-for-dilley-facility-stock-gains" target="_blank" rel="noreferrer noopener">Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Contracts

Movers

TDOC

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

<a href="https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-to-mass-produce-next-generation-cancer-drugs-in-Japan" title="https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-to-mass-produce-next-generation-cancer-drugs-in-Japan">https://asia.nikkei.com/Business/Pharmaceuticals/Novartis-to-mass-produce-next-generation-cancer-drugs-in-Japan</a>

Global

'Novartis To Mass Produce Next-Generation Cancer Drugs In Japan' - Nikkei Asia

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) released data Sunday on its Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH study for Xolair (omalizumab) for one or more food allergies.
Stage 2 of the OUtMATCH study showed Xolair was more effective with fewer side effects than multi-allergen oral immunotherapy (OIT) in the first-ever head-to-head trial comparing the two treatment approaches.
<ul>
<li>In the first head-to-head trial comparing Xolair to OIT, the <a href="https://www.roche.com/media/releases/med-cor-2025-03-02" target="_blank" rel="noreferrer noopener">study</a> met its primary endpoint, showing 36% of food allergy patients treated with Xolair monotherapy could tolerate at least 2,000 mg of peanut protein and two other food allergens without experiencing an allergic reaction, compared to 19% in the OIT group.</li>
<li>These findings were largely driven by the high rates of adverse events (AEs) in the OIT group.</li>
<li>Serious AEs (30.5% for OIT vs. 0% for Xolair), AEs leading to treatment discontinuation (22% vs. 0%), and AEs treated with epinephrine (37.3% vs. 6.9%) were all more common in the OIT group.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42597251/roche-prothena-partnered-mid-stage-parkinsons-trial-misses-primary-endpoint-but-cling-on-signs-of-clinical-benefits" rel="noreferrer noopener">Roche-Prothena Partnered Mid-Stage Parkinson&#8217;s Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits</a>
Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into a patient&#8217;s diet after stopping Xolair.
Stage 3 is ongoing, and study investigators continue to analyze data from additional patients who completed Stage 2 and then entered Stage 3.
In the US, Genentech, a member of the Roche Group, and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) are co-developing and co-promoting Xolair.
Last February, the FDA approved Xolair for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older <a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37182116/fda-approves-xolair-as-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-aller" rel="noreferrer noopener">with IgE-mediated food allergy</a>.
Price Action: RHHBY stock closed at $41.74 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/44054841/specialty-pharma-amphastar-stock-falls-on-lower-than-expected-q4-earnings-analyst-sees-competitive-headwinds" target="_blank" rel="noreferrer noopener">Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds</a></li>
</ul>
Image: Shutterstock

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy

Novartis Announces Presentation Of 17 Abstracts At 2025 AAAAI/WAO And AAD Meetings, Featuring Phase III REMIX-1/2 Data On Remibrutinib For Chronic Urticaria, Long-Term Cosentyx Data In Hidradenitis Suppurativa, And Phase II Patient Outcomes For Remibrutinib In HS

A federal court rejected Novartis Pharmaceuticals&#8217;, a unit of Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate constitutional protections against excessive fines, unlawful takings, or compelled speech.
The court determined that pharmaceutical manufacturers are not legally required to participate in the program, and those that do must adhere to its terms.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43629559/novartis-to-beef-up-heart-disease-offering-with-3-billion-blackstone-backed-anthos-therapeutics-deal" rel="noreferrer noopener">Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal</a>
For over 30 years, Congress has imposed price ceilings on prescription drugs purchased by federal agencies, including the Departments of Defense and Veterans Affairs.
These agencies also have the authority to negotiate prices below these limits. The Inflation Reduction Act of 2022 expanded this model by granting the Department of Health and Human Services (HHS) similar authority to negotiate prices for Medicare-covered drugs that lack generic competition and constitute a significant portion of Medicare spending.
Under the law, the Centers for Medicare &amp; Medicaid Services (CMS) can negotiate prices for high-expenditure drugs. Manufacturers who disagree with the program&#8217;s terms or the proposed pricing are not legally obligated to participate.
Novartis, however, <a target="_blank" href="https://storage.courtlistener.com/recap/gov.uscourts.ca3.123657/gov.uscourts.ca3.123657.25.0_1.pdf" rel="noreferrer noopener">argued</a> that the program imposed unconstitutional burdens, challenging it on three grounds: that it violated the Eighth Amendment&#8217;s prohibition on excessive fines, the Fifth Amendment&#8217;s protection against takings without just compensation, and the First Amendment&#8217;s ban on compelled speech.
The court dismissed Novartis&#8217; Eighth Amendment claim, citing the Anti-Injunction Act, which prevents lawsuits challenging the constitutionality of a tax before it is enforced.
Additionally, the court ruled that the program does not amount to a government taking under the Fifth Amendment, as it does not forcibly seize or mandate the sale of the company&#8217;s drugs.
Instead, the government offers to purchase medications under specific terms, which Novartis can choose to accept or decline. If a company finds the negotiated price unfavorable but still opts to sell, it does not constitute an unlawful taking.
Price Action: NVS stock is down 1.64% at $107.83 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43977188/nrg-energy-beats-q4-eps-estimates-unveils-ai-power-expansion-and-reaffirms-2025-growth-outlook" target="_blank" rel="noreferrer noopener">NRG Energy Beats Q4 EPS Estimates, Unveils AI Power Expansion, And Reaffirms 2025 Growth Outlook</a></li>
</ul>
Photo: Courtesy of Satur via Shutterstock

Government

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).</a>
&nbsp;
<h2>Situation Update</h2>
February 26, 2025 &ndash; CDC continues to respond to the public health challenge posed by a multistate outbreak of avian influenza A(H5N1) virus, or &quot;H5N1 bird flu,&quot; in dairy cows, poultry, and other animals in the United States. CDC is working in collaboration with the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), Administration for Strategic Preparedness and Response (ASPR), state public health and animal health officials, and other partners using a <a href="https://www.cdc.gov/one-health/about/index.html">One Health approach</a>.

CVAC

MRNA

NVAX

CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website

Macro Economic Events

Econ #s

Economics

U.S. Agriculture Secretary Brooke Rollins Says USDA Will Invest Up To $1B In Strategy To Curb Avian Flu; USDA Is Not Yet Authorizing Use Of Bird Flu Vaccines For Chickens

Novartis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) short percent of float has fallen 4.55% since its last report. The company recently reported that it has 4.08 million shares sold short, which is 0.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Novartis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740574814_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novartis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novartis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Novartis's peer group average for short interest as a percentage of float is 4.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Novartis?

Novartis Shares Fall After Reuters Reports Block Trade

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side effects.
At Charing Cross Hospital in London, about 170 multiple sclerosis patients experienced complications, including relapses, mobility issues, fatigue, pain, and weight gain. Some cases were severe enough to require hospitalization.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43792922/biogen-strengthens-pipeline-with-stoke-therapeutics-dravet-syndrome-candidate-via-multi-million-dollar-deal" rel="noreferrer noopener">Biogen Strengthens Pipeline With Stoke Therapeutic&#8217;s Dravet Syndrome Candidate Via Multi-Million Dollar Deal</a>
According to The Guardian report, NHS England has been rolling out biosimilar drugs like Tyruko since April, aiming to cut costs by using alternatives to patented medications. Biosimilars are designed to be as effective and safe as the original drugs but are considerably cheaper—Tyruko costs an average of 72% <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673992/biogen-delivers-q4-beat-analyst-focuses-on-leqembi-expansion-2025-outlook" rel="noreferrer noopener">less than Tysabri</a>.
Sandoz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>), a generic spin-off of Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), manufactures Tyruko. As per The Guardian <a target="_blank" href="https://www.theguardian.com/society/2025/feb/24/ms-patients-suffer-side-effects-after-nhs-england-switches-to-cheaper-drug" rel="noreferrer noopener">report</a>, the initiative is part of a broader strategy to save $1.26 billion (1 billion pounds) over five years on medication expenses.
The extent of the issue remains unclear. NHS England has stated that problems have only been observed at Charing Cross, but one patient claims that individuals at 15 other hospitals have also experienced negative effects from the switch.
Approximately half of the NHS hospitals treating MS patients are currently participating in the transition to Tyruko.
Due to growing concerns, NHS England is now discussing with the Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency to assess the situation and determine potential next steps.
Imperial College Healthcare NHS Trust, which oversees Charing Cross Hospital, initially had 345 patients on Tysabri. When the transition to Tyruko began in May, the trust anticipated mild, short-term side effects but was unprepared for the severity and persistence of complications. About half of the affected patients reported worsening symptoms over several months. In response, all have now been switched back to Tysabri.
Price Action: BIIB stock is up 0.19% at $140.91 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43909695/dominos-pizza-posts-q4-earnings-below-estimates-stock-falls" target="_blank" rel="noreferrer noopener">Domino&#8217;s Pizza Q4 Same Store Sales Growth Lags, Proposes 15% Dividend Hike</a></li>
</ul>
Photo by Tada Images via Shutterstock

Topics

SDZNY

SDZXF

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a>

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

<a href="https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html" title="https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html">https://www.newswire.ca/news-releases/novartis-receives-health-canada-approval-for-fabhalta-r-oral-treatment-for-adult-patients-with-pnh-861589075.html</a>

Novartis Gets Health Canada Approval For Fabhalta Oral Treatment For Adult Patients With PNH

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Shweta Khajuria downgraded the rating for The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) from Outperform to In-Line and lowered the price target from $135 to $90. Trade Desk shares closed at $122.23 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Tom Curran downgraded the rating for Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) from Buy to Neutral. Aspen Aerogels shares closed at $11.75 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Charles Neivert downgraded Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) from Overweight to Neutral and lowered the price target from $41 to $33. Olin shares closed at $27.98 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston downgraded the rating for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral. Novartis shares closed at $107.00 on Wednesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded The Kraft Heinz Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) from Buy to Underperform and lowered the price target from $36 to $33. Kraft Heinz shares closed at $28.62 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KHC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png" alt="" class="wp-image-780861" style="width:546px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13075746/image-2-39.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

UBS analyst Matthew Weston downgrades Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral.

UBS Downgrades Novartis to Neutral

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, <a target="_blank" href="https://www.benzinga.com/quote/NVS" rel="noreferrer noopener">clinical-stage biopharmaceutical company</a>.
Anthos is developing abelacimab, a late-stage medicine to prevent stroke and systemic embolism in patients with atrial fibrillation, a type of irregular heartbeat, or arrhythmia, that occurs when the upper chambers of the heart beat irregularly.
Novartis will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront" rel="noreferrer noopener">pay</a> an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.
The transaction is expected to close in the first half of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43380284/novartis-q4-earnings-beat-estimates-ceo-dismisses-entresto-patent-expiration-worries" rel="noreferrer noopener">Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries</a>
The transaction aligns with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Abelacimab is a fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
Phase 2 data showed a significant reduction in bleeding events in patients taking abelacimab versus a standard-of-care direct-oral anticoagulant in patients with atrial fibrillation.
Three Phase 3 trials are ongoing for patients at risk of arterial and venous clots, one in patients with atrial fibrillation and two in cancer-associated thrombosis.
In July 2022 abelacimab received an FDA Fast Track Designation for thrombosis associated with cancer.
In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
In November, Novartis acquired&nbsp;Kate Therapeutics to enhance and strengthen its <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42115127/novartis-confident-in-growth-as-it-elevates-midterm-sales-forecast-ceo-narasimhan-highlights-robust-pipeline-supporting-long-term-strategy" rel="noreferrer noopener">portfolio of gene therapies</a>.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Price Action: NVS stock is down 0.31% at $106.52 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43611591/behind-marvell-techs-multi-fold-growth-rd-acquisitions-and-ai-infrastructure" target="_blank" rel="noreferrer noopener">Behind Marvell Tech&#8217;s Multi-Fold Growth: R&amp;D, Acquisitions And AI Infrastructure</a></li>
</ul>
Image: Shutterstock

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal

Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab's potential to provide superior safety
Culminates growth journey as part of Blackstone Life Science

Blackstone-Backed Anthos Therapeutics To Be Acquired By Novartis In $3.1B Deal, Advancing Factor XI Inhibitor Therapy

Super Bowl LIX aired on Sunday, Feb. 9, 2025 and the Philadelphia Eagles defeated the Kansas City Chiefs 40-22, ending the Chiefs' attempt to be the first three-peat <a href="https://www.benzinga.com/general/sports/25/02/43583513/eagles-fly-over-chiefs-40-22-as-super-bowl-lix-tests-potential-137-million-viewership-for-fox">Super Bowl winners.</a>
The game also featured dozens of commercials advertising products and showcasing new movies and television shows. They also featured many celebrity cameos.
What Happened: Super Bowl LIX commercials were <a href="https://www.benzinga.com/general/sports/25/02/43560232/super-bowl-lix-commercials-ai-celebs-muppets-warren-buffett-linked-brand-take-the-spotlight">priced between $7 million and $8 million</a> for a 30-second slot by Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>), which had the media rights to the game.
Fox was able to secure $8 million or more for some last-second advertising inventory ahead of Sunday's game.
This author tracked all the commercials, from the singing of the National Anthem to the final round of ads after the Eagles won the Super Bowl. View the 2024 and 2023 Super Bowl commercials <a href="https://www.benzinga.com/general/sports/24/02/37076429/super-bowl-commercials-2024-complete-list-of-super-bowl-lviii-ads-and-companies-behind-them">here </a>and <a href="https://www.benzinga.com/general/entertainment/23/02/30883140/super-bowl-commercials-2023-the-complete-list-of-super-bowl-lvii-ads-and-the-companies-behi">here</a>. 
The tweet below shows the Super Bowl LIX commercial tracking in real time during the big game.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Super Bowl LIX Commercial Thread. Feel free to retweet. After National Anthem: Misson: Impossible The Final Reckoning Trailer <a href="https://twitter.com/search?q=%24PARA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PARA</a> Sketches <a href="https://twitter.com/search?q=%24SKX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SKX</a> TurboTax <a href="https://twitter.com/search?q=%24INTU&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$INTU</a> NASCAR on Fox <a href="https://twitter.com/search?q=%24FOX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$FOX</a> After Con Toss: Lilo &amp; Stitch Live Action Spot <a href="https://twitter.com/search?q=%24DIS&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DIS</a> YouTubeTV <a href="https://twitter.com/search?q=%24GOOG&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$GOOG</a>
&mdash; Chris Katje (@chriskatje) <a href="https://twitter.com/chriskatje/status/1888740049883173010?ref_src=twsrc%5Etfw">February 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Here&#8217;s a list of the Super Bowl LIX commercials and the companies behind them.
After National Anthem:
<ul>
<li>"Mission: Impossible – The Final Reckoning" Trailer, Paramount (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDA:PARAA)</li>
<li>Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>)</li>
<li>TurboTax, brand of Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)</li>
<li>NASCAR on Fox</li>
</ul>
After Coin Toss:
<ul>
<li>Lilo &amp; Stitch live action movie teaser for Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>)</li>
<li>YouTube TV, brand of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)</li>
</ul>
After Kickoff, During First Quarter:
<ul>
<li>Dunkin'</li>
<li>"How to Train Your Dragon" live action movie trailer, Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</li>
<li>"Thunderbolts" trailer, Marvel film from Disney</li>
<li>MSC Cruises</li>
<li>Little Caesars</li>
<li>Fox News</li>
<li>T-Mobile (NASDA:TMUS) with Starlink</li>
<li>Homes.com, brand of CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with Ray-Ban</li>
<li>IndyCar racing on Fox</li>
<li>Doritos, brand of PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>)</li>
<li>Cirkul</li>
<li>Michelob Ultra, brand of Anheuser-Busch InBev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>)</li>
</ul>
After End of First Quarter, During Second Quarter:
<ul>
<li>Disney+ and Hulu streaming platforms</li>
<li>Ritz, brand of Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>)</li>
<li>Red Bull</li>
<li>Squarespace</li>
<li>"The Floor" on Fox</li>
<li>Local Ad</li>
<li>Mountain Dew Baja Blast, brand of PepsiCo</li>
<li>Instacart, brand of Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>)</li>
<li>Coors Light, brand of Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</li>
<li>Stand Up to Hate</li>
<li>FanDuel Kick of Destiny challenge, brand of Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>)</li>
<li>"Extracted" on Fox</li>
<li>Uber Eats, brand of Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>)</li>
<li>WeatherTech</li>
<li>TurboTax, brand of Intuit</li>
<li>NASCAR on Fox</li>
<li>Google Pixel phone with Gemini AI</li>
<li>UFL on Fox</li>
<li>Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>)</li>
<li>He Gets Us</li>
<li>Liquid Death</li>
<li>HexClad</li>
<li>Duracell, brand of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)</li>
<li>OpenAI</li>
<li>CoffeeMate, brand of Nestle (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>)</li>
<li>NFL youth organizations</li>
<li>Ram Truck, brand of Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>)</li>
<li>Hellmann's, brand of Unilever (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)</li>
<li>Pringles, brand of Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>)</li>
<li>Budweiser, brand of Anheuser-Busch InBev</li>
<li>Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)</li>
<li>NYU Langone Health</li>
<li>Novartis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)</li>
</ul>
After End of Second Quarter, During Halftime, During Third Quarter:
<ul>
<li>IndyCar on Fox</li>
<li>MyFitnessPal</li>
<li>Yahoo!, brand of Apollo Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Verizon Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</li>
<li>Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</li>
<li>Jewel-Osco, brand of Albertsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>)</li>
<li>Bayer Aspirin</li>
<li>"The Masked Singer" on Fox</li>
<li>Fox Nation streaming platform</li>
<li>On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>)</li>
<li>Angel Soft, brand of Georgia-Pacific</li>
<li>Reese's Lava Cup, brand of The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
<li>NFL ad</li>
<li>Tubi streaming platform, brand of Fox</li>
<li>Fox shows</li>
<li>Local ad</li>
<li>Local ad</li>
<li>Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>)</li>
<li>DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>)</li>
<li>Meta Platforms</li>
<li>Stand Up to Hate</li>
<li>Nerds</li>
<li>Lay's, brand of PepsiCo</li>
<li>"M3gan 2.0" trailer, distributed by Comcast</li>
<li>Taco Bell, brand of Yum! Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>)</li>
<li>Nerdwallet</li>
<li>Häagen-Dazs</li>
<li>Tubi</li>
<li>Fox Nation</li>
<li>Bud Light, brand of Anheuser-Busch InBev</li>
<li>Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>)</li>
<li>Poppi</li>
<li>TV shows on Fox</li>
</ul>
After End of Third Quarter, During Fourth Quarter:
<ul>
<li>Salesforce Inc</li>
<li>Ramp</li>
<li>Tullamore Dew whiskey</li>
<li>Toyota (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>)</li>
<li>Sandals Resorts</li>
<li>Local Ad</li>
<li>Jeep, brand of Stellantis</li>
<li>Tubi streaming platform</li>
<li>Fox News</li>
<li>Stella Artois, brand of Anheuser-Busch InBev</li>
<li>Dove, brand of Unilever</li>
<li>Booking.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>)</li>
<li>UFL on Fox</li>
<li>Bosch</li>
<li>Totino's Pizza Rolls, brand of General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>)</li>
<li>GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>)</li>
<li>Fetch</li>
<li>TV shows on Fox</li>
</ul>
End of Game, Eagles win 40-22, Final Ad Spot After Game:
<ul>
<li>Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>)</li>
<li>Adidas (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>)</li>
<li>Cirkul</li>
<li>Vrbo, brand of Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</li>
<li>Universal Resorts</li>
<li>Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</li>
</ul>
The list includes all the Super Bowl LIX commercials that aired from the playing of the national anthem to the first ad break after the Eagles won.
Read Also:<a href="https://www.benzinga.com/general/sports/25/02/43578857/if-you-invested-in-bitcoin-instead-of-buying-super-bowl-tickets-each-year-since-2012-heres-how-much-youd-have-today"> If You Invested in Bitcoin Instead of Buying Super Bowl Tickets Each Year Since 2012, Here&#8217;s How Much You&#8217;d Have Today</a>
Winners and Losers: While everyone will have their own favorites and ads they wish they'd never seen, here's a look at some of the winners and losers.
USA Today asks consumers to <a href="https://admeter.usatoday.com/2025">vote </a>on their favorite Super Bowl commercials each year via the Ad Meter.
Here are the top 10 highest rated ads as of Monday morning:
<ol>
<li>Budweiser – "First Delivery"</li>
<li>Lay's – "The Little Farmer"</li>
<li>Michelob Ultra – "The ULTRA Hustle"</li>
<li>Stella Artois – "David and Dave</li>
<li>NFL – "Somebody"</li>
<li>NFL – "Flag 50"</li>
<li>Bud Light – "Big Men on Cul-De-Sac"</li>
<li>Uber Eats – "Century of Cravings"</li>
<li>Hellmann's – "When Sally Met Hellmann's"</li>
<li>Pfizer – "Knock Out"</li>
</ol>
Here are the 10 lowest rated ads as of Monday morning:
<ol>
<li>Tubi – "The Z Suite"</li>
<li>Fetch – "The Big Reward"</li>
<li>CoffeeMate – "Foam Diva"</li>
<li>Cirkul – "You Got Cirkul"</li>
<li>OpenAI – "ChatGPT: The Intelligence Age"</li>
<li>Squarespace – "A Tale As Old As Websites"</li>
<li>T-Mobile – "A New Era in Connectivity"</li>
<li>DoorDash – "DashPass Math"</li>
<li>Hims &amp; Hers – "Sick of the System"</li>
<li>GoDaddy – "Act Like You Know"</li>
</ol>
The list of winners shows that Anheuser-Busch InBev continues the tradition of unforgettable Super Bowl beer ads once again, taking four places on the top 10 list.
The list of losers shows that companies like CoffeeMate and Hims &amp; Hers, which had their first ever Super Bowl commercials may not have hit the mark with consumers watching.
Read Next: 
<ul>
<li><a href="EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship">EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year&#8217;s NFL Championship</a></li>
</ul>
Photo: Shutterstock

Sports

ADDYY

BKNG

CART

CMCSA

CSGP

DASH

EXPE

FLUT

FOXA

GDDY

GOOG

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INTU

MDLZ

NSRGY

ONON

PARA

PARAA

STLA

TMUS

UBER

Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them

Small Cap

Opinion

Press Releases

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

GeminiBio Appoints Mike Stella to Board

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

ABBV

AMGN

ATOS

CCCC

DRIO

HOLX

IMGN

KZIA

ONCY

OSTX

PRTC

PTCT

TSX:ONC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Novartis

Noticias

Últimas noticias sobre Novartis (NYSE:NVS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL